Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Impact of the Launch of Adalimumab Biosimilars in Different Clinical and Pharmacy Settings

April 12th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.

The Top 5 Biosimilar Articles for the Week of April 8

April 12th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 8, 2024.

Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032

April 11th 2024

By Skylar Jeremias

Article

The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.

Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion

April 10th 2024

By Skylar Jeremias

Article

A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.

Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients

April 9th 2024

By Skylar Jeremias

Article

Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.

Biosimilar Business Recap: BI Layoffs; Teva, mAbxience Partnership; Phase 3 Keytruda Biosimilar Trial

April 8th 2024

By Skylar Jeremias

Article

After poor sales for its adalimumab biosimilar, Boehringer Ingelheim (BI) announces layoffs; Teva Pharmaceuticals and mAbxience partner on an oncology biosimilar; Samsung Bioepis begins a phase 3 trial for a biosimilar referencing Keytruda (pembrolizumab).

Streamlined Approach to Biosimilar Approval Reduces Litigation Risk

April 7th 2024

By Cameron Santoro

Video

Intellectual property attorney Ha Kung Wong, JD, describes the patent dance and how it is designed to streamline information exchange while avoiding unnecessary lawsuits by allowing early assessment of patent infringement and validity.

Meta-Analysis Confirms Similar Safety, Efficacy Between Adalimumab Biosimilars, Humira

April 6th 2024

By Deana Ferreri, PhD

Article

A systematic review and meta-analysis of 7 randomized controlled trials found no significant differences in efficacy and safety indicators between adalimumab biosimilars and the reference product (Humira) for treatment of moderate to severe psoriasis.

The Safety and Efficacy of Adalimumab Biosimilars in Inflammatory Diseases

April 5th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Specialists in rheumatology, dermatology and gastrointestinal disease discuss clinical trials that have shown safety and efficacy of adalimumab biosimilars in inflammatory diseases.

The Pharmacological Aspects of Adalimumab Biosimilars

April 5th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.